Grade My Investments
HomeFree Stock Grades › RXST

RxSight, Inc. (RXST) Stock Grade

RXST · Healthcare

C
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$429.1M
P/E Ratio
Revenue Growth (YoY)
-3.9%
Net Margin
-29.0%
Return on Equity
Dividend Yield
None

About RxSight, Inc.'s fundamentals

RxSight is a medical device company with a market capitalization of $429.1 million that reported a net loss in its latest annual statement, reflecting a negative net margin of -29.0%. The company experienced a slight revenue contraction of 3.9% year-over-year, indicating declining sales in its current operating period. With no dividend yield and the absence of positive profitability metrics, RxSight remains in a loss-making position as it continues its operations in the medical devices sector.

Track RXST free — no credit card required. Live grade + monthly AI report →